Anavex Life Sciences (AVXL) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Voyager Therapeutics (VYGR) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 55.1% versus a loss of 84.4%. Over five years, VYGR leads with a -42.2% price change compared with -91.2% for AVXL. Voyager Therapeutics is the larger company by market cap ($151.0 million vs $138.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | VYGR |
|---|---|---|
| Share price | $1.49 | $2.45 |
| Market cap | $138.12M | $150.96M |
| 1-day change | -3.25% | +3.38% |
| YTD return | -56.74% | -39.69% |
| 1-year return | -84.37% | -55.11% |
| 5-year return | -91.21% | -42.20% |
| EPS (TTM) | $-0.14 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.53 | $5.55 |
| 52-week low | $1.44 | $2.33 |
| Distance from 52-week high | -84.36% | -55.86% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | — | +507.76% |
| Average volume | 979.69K | 573.14K |
| Shares outstanding | 92.70M | 61.62M |
| Employees | 34 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VYGR has outperformed AVXL by 29.3 percentage points over the past year.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
AVXL vs VYGR FAQ
Which is bigger, Anavex Life Sciences or Voyager Therapeutics?
Voyager Therapeutics (VYGR) is larger, with a market capitalization of $150.96M compared with $138.12M for Anavex Life Sciences (AVXL).
Which stock has performed better over the past year, AVXL or VYGR?
VYGR returned -55.11% over the past 12 months, compared with -84.37% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.